76% of precision medicine trials miss recruitment targets. Genome2Protocol queries population-scale genomic biobanks against genomic eligibility criteria, returning data-driven patient pool estimates. We tell pharma where patients exist before they commit to a target, lock a protocol, or activate the wrong site.
